Phaseline

Companies › AviadoBio

AviadoBio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AVB-101
AAV9-delivered GRN gene therapy
GRNPhase 1Frontotemporal DementiaApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06064890AVB-101Phase 1Frontotemporal DementiaNeurologyApr 2027

Targets

GRN (1)

Companies with the same targets

Prevail Therapeutics Voyager Therapeutics Passage Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.